Monitor for additional Form 144 or Form 4 filings by other insiders. The concentrated selling by a former officer over a short period could precede further insider exits or indicate a lack of conviction ahead of upcoming catalysts.
TARS drugs
TARS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $82.76entry
- T+1 · 3mo ago +0.54%α −0.51% · $83.21
- T+5 · 2mo ago −1.98%α −1.02% · $81.12
- T+20 · 7w ago −5.01%α −4.68% · $78.61
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Former officer Aziz Mottiwala filed a Form 144 to sell 8,000 shares (~$654k) of Tarsus Pharmaceuticals. This follows substantial recent sales of 212,073 shares (~$15.4M) over the prior two weeks. While the proposed sale is small relative to market cap, the pattern of aggressive selling by a former officer may signal reduced confidence.
Key Facts
- Aziz Mottiwala (former officer) intends to sell 8,000 shares of common stock, estimated value $654,373.01.
- Shares were acquired on 07/27/2020 via stock option exercise.
- Mottiwala has already sold 53,043 shares on 08/19/2026, 81,332 shares on 08/25/2026, and 77,698 shares on 09/01/2026, totaling 212,073 shares (~$15.4M).
- Proposed sale represents ~0.02% of TARS's $3.2B market cap; recent sales total ~0.48%.
Financial Impact
Proposed sale of $654k is small; recent aggregate sales of ~$15.4M are more material and may weigh on sentiment.
Risk Factors
- Further insider selling could pressure the stock.
- The selling pattern may reflect negative private information about the company's outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-006653 |
| Document: 0001959173-26-006653-index.html | 0001959173-26-006653 |
| Document: 0001959173-26-006653.txt | 0001959173-26-006653 |
Track record
21 reports on TARS
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers